Similar companies
Income Statement (USD)
Q3 '24 | QoQ | |
---|---|---|
Revenue | 81M | 71.1% |
Gross Profit | 32M | 256% |
Cost of Revenue | 48M | 27% |
Operating expense | 32M | 22.5% |
Net Income | 20M | 548.6% |
EBITDA | 25M | 3323.5% |
Balance Sheet (USD)
Q3 '24 | QoQ | |
---|---|---|
Total Assets | 221M | 7.7% |
Total Liabilities | 150M | 4.4% |
Total Equity | 71M | 46.5% |
Shares Outstanding | 49M | 1.3% |
Cash Flow (USD)
Q3 '24 | QoQ | |
---|---|---|
Cash from operations | 11M | 928.7% |
Cash from investing | 260,000 | 63.2% |
Cash from financing | -11M | 1.3% |
EPS
Financial Highlights for Puma Biotechnology in Q3 '24
Puma Biotechnology reported a revenue of 81M, which is a 71.1% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 32M, marking a 256% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 48M, a 27% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 32M, showing a -22.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 20M, showing a 548.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 25M, showing a 3323.5% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
It was a positive quarter for Puma Biotechnology with growth in revenue, gross profit, and net income.